Introduction

Important note. The recommendations for KRAS use in people with metastatic colorectal cancer who may receive anti-EGFR antibody therapy, such as cetuximab (Erbitux)and panitumumab (Vectibix) have been updated since the publication of this guideline. The new recommendations are now reflected in a Provisional Clinical Opinion (PCO) on KRAS Testing.

Key Points:

• A tumor marker is a substance produced by the tumor or a person’s body in response to cancer.
  
  
• Tumor markers can help your doctor plan and monitor treatment.
  
  
• This patient guide recommends the use of different tumor markers for different types of gastrointestinal cancers; talk with your doctor about which tests are most appropriate for you.

To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) asks its medical experts to develop recommendations for specific areas of cancer care. ASCO developed a clinical practice guideline about tumor markers for colorectal and pancreatic cancers. This guide for patients is based on ASCO's recommendations.

As you read this guide, please keep in mind that every person treated for cancer is different. These recommendations are not meant to replace your judgment or that of your doctor. The final decisions you and your doctors make will be based on your individual circumstances.

Last Updated: April 13, 2009

| Next >